Empyrean Bio Labs

Empyrean Bio Labs

Shop

Sale!

Tesamorelin

Price range: $70.00 through $120.00

 A growth-hormone-releasing hormone analog that stimulates the body’s own production of growth hormone and IGF-1. Tesamorelin is valued for visceral-fat reduction, improved body composition, muscle quality, lipid metabolism, and reductions in liver fat. It is prescribed as Egrifta SV to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.

Research Details

Tesamorelin Scientific Research Overview Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing factor. It activates pituitary GHRF receptors, stimulating endogenous growth-hormone release and increasing downstream IGF-1 signaling. Research has focused primarily on visceral adipose tissue, body composition, lipid metabolism, liver fat, and growth-hormone-axis activity. Published Research Findings Randomized clinical research in adults with HIV-associated abdominal fat accumulation found that tesamorelin reduced visceral adipose tissue while generally preserving subcutaneous abdominal fat. Continued treatment maintained the reduction for up to 52 weeks and was also associated with improvements in body-image measurements and selected lipid markers. A separate six-month randomized study found that tesamorelin was associated with reductions in both visceral adipose tissue and liver fat. The liver-fat findings were described as promising but preliminary because the study was comparatively small and not designed to establish long-term clinical outcomes. A more recent evidence review found that the overall research supports improvements in visceral fat and selected body-composition and hepatic-fat measurements in populations with HIV-associated lipodystrophy. Evidence and Regulatory Context Specific tesamorelin prescription products are FDA approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. FDA labeling states that tesamorelin is not indicated for general weight-loss management and that long-term cardiovascular safety has not been established. Research Links Tesamorelin and Visceral-Fat Reduction Maintained for 52 Weeks Effect of Tesamorelin on Visceral Fat and Liver Fat FDA EGRIFTA SV Prescribing Information FDA EGRIFTA WR Prescribing Information Research Context: Published findings summarized on this page involve controlled studies of the named molecule and FDA-reviewed pharmaceutical formulations. These findings do not establish the identity, purity, sterility, safety, effectiveness, or regulatory status of the research material offered on this page. This product is sold strictly for lawful laboratory research and is not intended for human or veterinary use.

StorageStorage Information: Store lyophilized research material tightly sealed, dry, and protected from light at -4°F (-20°C) or below for long-term stability. After laboratory preparation, store in small aliquots according to the product and avoid repeated freeze-thaw cycles; allow cold vials to reach room temperature before opening to minimize condensation.
Compliance Notice: For research use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease. Products and information are intended for qualified adult researchers only.

Description

Tesamorelin is a growth-hormone-releasing hormone analog that stimulates the pituitary gland to increase the body’s natural production of growth hormone. This subsequently raises IGF-1 signaling and supports pathways involved in visceral-fat metabolism, body composition, tissue maintenance, lipid regulation, and muscle quality. Unlike compounds that supply growth hormone directly, tesamorelin works through the body’s existing endocrine system and preserves the natural signaling relationship between the hypothalamus, pituitary gland, and peripheral tissues.

Clinical research has demonstrated meaningful reductions in visceral abdominal fat, the metabolically active fat stored around the internal organs. Tesamorelin has also been studied for reductions in liver fat and improvements in body-composition measurements. Prescription tesamorelin, marketed as Egrifta SV and Egrifta WR, is used to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Its combination of established clinical use and powerful metabolic research potential has made tesamorelin a standout compound in body-composition, growth-hormone, visceral-fat, and longevity-clinic discussions.

Additional information

Strength

10 mg, 20 mg

Reviews

There are no reviews yet.

Be the first to review “Tesamorelin”

Your email address will not be published. Required fields are marked *